Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of Three Doses of an Inactivated SARS-CoV-2 Vaccine in Chinese Pulmonary Tuberculosis Patients Aged 18-75 Years: a Randomized, Double-blind, Parallel-controlled Clinical Trial

NCT05148949 is registered in ClinicalTrials.gov with Jiangsu Province Centers for Disease Control and Prevention as lead sponsor.

NCT NCT05148949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05148949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of Three Doses of an Inactivated SARS-CoV-2 Vaccine in Chinese Pulmonary Tuberculosis Patients Aged 18-75 Years: a Randomized, Double-blind, Parallel-controlled Clinical Trial
Lead sponsor
Jiangsu Province Centers for Disease Control and Prevention
Phase
Phase 4
Overall status
Unknown status
Start date
December 22, 2021
Completion date
March 10, 2023
Enrollment
240 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, pulmonary tuberculosis